Roche's Avastin wins EU approval for treatment of non-small cell lung cancer |
|
|
|
Published
:
Fri, 24 Aug 2007 06:59 |
ZURICH (Thomson Financial) - Roche Holding AG said its cancer treatment Avastin has been approved in Europe for the first-line treatment of patients with advanced non-small cell lung cancer (NSCLC), in combination with platinum-based chemotherapy.NSCLC is the most common form of lung cancer, a difficult to treat disease, killing over 3,000 people per day worldwide.andrew.ge.thompson@thomson.comat/jlw/at/jlwCOPYRIGHTCopyright AFX News Limited 2007. All rights reserved.The copying, republication or redistribution of AFX News Content, including by framing or similar means, is expressly prohibited without the prior written consent of AFX News.
|
|
|
|